Sun Pharma inks deal to commercialize Winlevi in Canada and the U.S.
Category: #business  By Pranali Mehta  Date: 2021-07-27
  • share
  • Twitter
  • Facebook
  • LinkedIn
Sun Pharma inks deal to commercialize Winlevi in Canada and the U.S.
  • Cassiopea S.p.A will be the exclusive supplier, as per the new agreement.
  • Sun Pharma’s share price grew by 1.06% to 9.43 USD following the announcement.

Sun Pharmaceutical Industries Limited announced to have signed an agreement with Cassiopea S.p.A to commercialize Winlevi (clascoterone cream 1%) in Canada and the United States. Sun Pharma’s share price grew by 1.06% to 9.43 USD following its recent announcement.

As per the agreement, Sun Pharma will own the exclusive rights to commercialize Winlevi in Canada and the United States while Cassiopea will be the exclusive supplier. Moreover, the Italy-based pharmaceutical company will receive an upfront payment of USD 45 million in addition to commercial milestones worth USD 190 million.

The United States Food and Drug Administration had approved Winlevi (clascoterone cream 1%) for topical treatment of acne vulgaris among patients who are 12 years of age and older. The last time the FDA approved an acne drug with an advanced mechanism was approximately 40 years ago.

Notably, acne is the most common skin condition in the U.S. and affects up to 50 million Americans each year. Winlevi should be available in the United States by October 2021.

CEO of North America Sun Pharma, Abhay Gandhi was quoted saying that the company is pleased to collaborate with Cassiopea. He further added that the addition of Winlevi in the company’s product portfolio will strengthen its presence in the acne treatment vertical. 

Meanwhile, Cassiopea CEO Diana Harbort mentioned that the new agreement will help the company to leverage Sun Pharma’s strong presence in U.S. dermatology. The transaction will also allow Cassiopea to generate substantial returns, which will further benefit the development of pipeline drugs.

Sun Pharmaceutical Industries Limited is India’s top pharmaceutical company and the world’s fourth-largest generic pharma company.

Source Credits—

https://www.business-standard.com/article/news-cm/sun-pharma-gains-on-deal-for-acne-cream-with-cassiopea-121072600552_1.html

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Pranali Mehta

Pranali Mehta    

Pranali Mehta boasts of over three years of experience as a content writer. Having completed her graduation in chemical engineering, she worked as safety & environment associate in a chemical company for a year. Harnessing her passion for writing however, Pranali deci...

Read More >>

More News By Pranali Mehta

Petrofac collabs with Hitachi over offshore joint grid integration
Petrofac collabs with Hitachi over offshore joint grid integration
By Pranali Mehta

Petrofac, an international energy services company, and Hitachi Energy have recently collaborated to provide a joint grid integration and linked infrastructure for supporting the fast-growing offshore wind market. As per sources, this collaboratio...

Street Lighting Control System Market Size, Share to Generate Lucrative Revenues By 2028
Street Lighting Control System Market Size, Share to Generate Lucrative Revenues By 2028
By Pranali Mehta

The research report on Street Lighting Control System market Added by Market Study Report proposes a comprehensive study on the recent industry trends. In addition, the report presents a detailed abstract of the growth statistics, revenue estimation,...

Medical Crowdfunding Platform Market Size, Share to Witness Notable Hike Over 2022-2028
Medical Crowdfunding Platform Market Size, Share to Witness Notable Hike Over 2022-2028
By Pranali Mehta

The latest report on ' Medical Crowdfunding Platform market' Added by Market Study Report provides a concise analysis of the industry size, revenue forecast and regional spectrum of this business. The report further illustrates the major challenges a...